Clinical study with birch pollen hypoallergen DM-101 continues

First-in-Human clinical study with birch pollen hypoallergen DM-101 has been restarted after a temporary halt. In early 2020, Desentum initiated a clinical study to evaluate the safety and tolerability of DM-101, a hypoallergen designed for...

Syys-lokakuussa on mahdollisuus sijoittaa Desentumiin

Desentumin joukkorahoituskierros käynnistyi 17.9.2019 Desentum on aloittamassa kliiniset tutkimukset ensimmäisellä immunoterapeuttisella tuotteellaan, DM-101:llä, joka on suunnattu koivuallergian hoitoon. Tuotteella pyritään koivuallergian...

Desentum raises EUR 2.3 million to test allergy vaccine

Desentum is progressing towards clinical stage with its first immunotherapeutic product targeting birch pollen allergy. It has raised approx. EUR 2.3 million in a crowd funding campaign arranged by a Finnish investment service company...

Desentum in the media

Here you can find links to articles about Desentum in international media. To see articles in Finnish media, change the language to Finnish from the upper right corner.

This Hypoallergenic Vaccine Could Alleviate Hay Fever Faster Than Approved Vaccines

Desentum selected for EUR 1.9 million EU grant

Biopharmaceutical company Desentum wins EU grant

Finnish Scientists Discover Vaccine to Eliminate Allergies